The Evidence Based Rheumatology Podcast
Health & Fitness:Medicine
Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast. I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this! This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends!
E25: MAINRITSAN 2 - Fixed vs. Tailored Rituxan for AAV
E24: Intra-articular Steroid vs. Placebo for Knee OA
E23: Stress Related Disorders and Subsequent Autoimmune Disease
E22: Ustekinumab for Giant Cell Arteritis
E21: ACE Levels for Sarcoidosis
E20: Rituxan vs. Cytoxan for AAV - The RAVE Trial
E19: Clinical Utility of a Positive ANA
E18: Triple Therapy for Catastrophic Antiphospholipid Syndrome
E17: Steroids and the Risk of Scleroderma Renal Crisis
E16: Tocilizumab in Giant-Cell Arteritis - GIACTA
E15: The Ribosomal P Isn't Useful in NPSLE
E14: Cardiovascular Safety of Febuxostat
E13: Withdrawing HCQ in SLE
E12: ACR 2015 Workforce Study - the Rheumageddon!
E11: Development and Validation of the HScore
E10: Abatacept in RA-ILD
E9: Rituximab in Myositis - The RIM Trial
E8: Mepolizumab or Placebo for EGPA
E7: The ALMS Trial - MMF vs CYC for Lupus Nephritis
E6: Methylprednisolone and Cyclophosphamide, Alone or in Combinatinon, for Lupus Nephritis
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive